Background and Aims: Herpes simplex virus type 1 (HSV-1) is a widespread herpetic pathogen responsible for recurring mucocutaneous infections that are frequently debilitating and difficult to treat. The objective of this work was to design and study the efficiency of a biosurfactant–synthetic surfactant hybrid nanoemulgel (NEG) system with antiviral activity against HSV-1 using Melissa officinalis and Illicium verum essential oils.
Methods: Nanoemulsions (NEs) were prepared through ultrasonic emulsification and stabilised using Quillaja saponaria saponins and Kolliphor® P 188. Selected NEs were mixed into xanthan gum-based gels to create NEGs. The formulations were assessed for their physicochemical properties, rheological behaviour, and stability. The CCK-8 assay was employed to evaluate the in vitro cytotoxicity on Vero cells. The antiviral activity against HSV-1 was assessed by measuring the tissue culture infectious dose 50% (TCID₅₀) values.
Results: Optimized NEGs demonstrated stable nano-sized droplets, a negative zeta potential, shear-thinning rheology, and preserved structural integrity throughout a 3-month storage duration. Both test (T) and placebo (P) formulations demonstrated dose-dependent cytotoxicity; however, T exhibited marginally lower cytotoxicity across all dilutions. Antiviral studies demonstrated that T significantly decreased the HSV-1 titre by 17.78-fold at a 1/2000 dilution compared with the untreated control, whereas P resulted in only a 1.77-fold reduction, thereby confirming the role of essential oils in antiviral efficacy.
Conclusion: The developed NEG incorporating essential oils from Melissa officinalis and Illicium verum demonstrated notable antiviral activity against HSV-1, along with satisfactory cytocompatibility. The results indicate its potential effectiveness as a topical antiviral treatment for managing HSV-1 infections.
Antiviral Activity Essential Oils Herpes Simplex Virus Melissa officinalis Nanoemulgel Star Anise
| Primary Language | English |
|---|---|
| Subjects | Pharmaceutical Delivery Technologies |
| Journal Section | Research Article |
| Authors | |
| Submission Date | April 17, 2025 |
| Acceptance Date | October 1, 2025 |
| Publication Date | January 14, 2026 |
| DOI | https://doi.org/10.26650/IstanbulJPharm.2025.1677873 |
| IZ | https://izlik.org/JA86YC95ML |
| Published in Issue | Year 2025 Volume: 55 Issue: 3 |